NASDAQ:SPRE 4 January 2026 - 23 February 2026

Spyre Therapeutics shares dropped 4.2% to $41.38 in premarket trading Monday after a 14.3% surge Friday. The move follows Thursday’s filing of a $500 million shelf registration, raising dilution concerns. Investors are watching for initial Phase 2 ulcerative colitis data, expected in the second quarter of 2026. Spyre ended 2025 with $757 million in cash and marketable securities.

Spyre Therapeutics shares dropped 6.6% to $30.58 on Friday, closing near session lows after about 889,000 shares traded. The move followed comments from Philadelphia Fed President Anna Paulson signaling rate cuts may be delayed. Spyre remains below its 52-week high of $34.49, with traders eyeing whether the stock can hold above $30 at Monday’s open. No significant company news has been released since the last quarterly update.